Zhang Xiangwen, Zhou Tingting, Li Wenbin, Zhang Taotao, Che Ninwei, Zu Guo
Department of Gastroenterology Surgery, The Dalian Municipal Central Hospital Affiliated of Dalian Medical University, Dalian 116044, PR China.
Department of Neurology, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, PR China.
Pathol Res Pract. 2018 Aug;214(8):1105-1109. doi: 10.1016/j.prp.2018.06.005. Epub 2018 Jun 12.
Few studies have reported the clinical and prognostic significance of C/EBP homologous protein (CHOP) in advanced gastric cancer (GC). Therefore, the present study investigated the expression of CHOP in advanced GC patients to determine its potential prognostic role.
The levels of CHOP in 95 patients with advanced GC and adjacent non-cancerous tissues were evaluated by qRT-PCR, western blot and immunohistochemistry. Furthermore, the association of CHOP expression with clinicopathological parameters and prognosis of advanced GC patients was analyzed.
The levels of CHOP were down-regulated in advanced GC compared with non-cancerous tissues (P<0.01). In addition, high CHOP expression more frequently occurred in advanced GC tissues with depth of invasion of T (P < 0.01), lower clinical stage (TNM Ⅰ-Ⅱ stage) (P<0.05) and without lymph node metastasis (P<0.05). No significant difference was observed between the expression of CHOP and age, gender, tumor size, lesion site and differentiation (P>0.05). The Kaplan-Meier survival analyses showed that the overall survival rate of advanced GC patients with positive CHOP expression was significantly higher than that of patients with negative CHOP expression (P<0.01). Univariate and multivariate Cox proportional hazards models revealed that low CHOP expression (OR = 0.314, 95%CI: 0.176～0.794, P = 0.003) was an independent factor for poor overall survival in advanced GC patients.
Low expression of CHOP predicts the poor prognosis of advanced GC patients, and CHOP may be a prognostic biomarker for patients with advanced GC.
很少有研究报道C/EBP同源蛋白（CHOP）在晚期胃癌（GC）中的临床及预后意义。因此，本研究调查了CHOP在晚期GC患者中的表达情况，以确定其潜在的预后作用。
采用qRT-PCR、蛋白质免疫印迹法和免疫组织化学法评估95例晚期GC患者及其癌旁非癌组织中CHOP的水平。此外，分析了CHOP表达与晚期GC患者临床病理参数及预后的相关性。
与非癌组织相比，晚期GC中CHOP水平下调（P<0.01）。此外，CHOP高表达更常见于浸润深度为T的晚期GC组织（P<0.01）、临床分期较低（TNMⅠ-Ⅱ期）（P<0.05）且无淋巴结转移的组织（P<0.05）。CHOP表达与年龄、性别、肿瘤大小、病变部位及分化程度之间未观察到显著差异（P>0.05）。Kaplan-Meier生存分析显示，CHOP表达阳性的晚期GC患者的总生存率显著高于CHOP表达阴性的患者（P<0.01）。单因素和多因素Cox比例风险模型显示，CHOP低表达（OR=0.314，95%CI：0.176～0.794，P=0.003）是晚期GC患者总生存不良的独立因素。
CHOP低表达预示晚期GC患者预后不良，CHOP可能是晚期GC患者的一种预后生物标志物。
